You are here: Industry Insights > GenScript ProBio

News List

Successful Groundbreaking Ceremony for GenScript ProBio to Expand Commercial cGMP Plasmid and Viral Vector Manufacturing Facility in Zhenjiang, China prnasia
January 21, 2022
GenScript ProBio, a global antibody and gene therapy contract development and manufacturing organization (CDMO), has announced 2022 manufacturing expansion plans to meet the increasing demand for commercial cGMP...
GenScript ProBio, Abogen Biosciences and Walvax Biotechnology Enter into Collaboration on BLA and Commercial Manufacturing of mRNA Vaccine prnasia
November 30, 2021
GenScript ProBio, Suzhou Abogen Biosciences Technology Co. ("Abogen Biosciences") and Walvax Biotechnology Co. ("Walvax Biotechnology") announced a collaboration on commercial manufacturing...
GenScript ProBio and AskGene Enter into a Non-exclusive License of A sdAb Targeting Immune Checkpoint Target prnasia
September 28, 2021
On September 26, 2021, GenScript ProBio and AskGene signed a license agreement for GenScript ProBio's single-domain antibody (sdAb) targeting an immune checkpoint target.
Initium Therapeutics Launches Antibody Development Platform contractpharma
December 10, 2020
On December 7, 2020, GenScript ProBio and Initium Therapeutics announced that Initium Therapeutics has launched a single B-cell based antibody development platform through collaboration with GenScript ProBio.
Through Strategic Collaboration with GenScript ProBio, Initium Therapeutics Plans to Utilize GenScript ProBio's Berkeley Lights Beacon Platform to Expand Their Antibody Drug Pipeline prnasia
December 08, 2020
On December 7, 2020, GenScript ProBio and Initium Therapeutics announced that Initium Therapeutics has launched a single B-cell based antibody development platform through collaboration with GenScript ProBio.
GenScript ProBio Congratulates XLifeSc on FDA Allowance of IND Application for TCR-T Program prnasia
September 27, 2020
On September 24, XiangXue Life Sciences (XLifeSc), a partner of GenScript ProBio, announces FDA allowance of its IND application for TCR-T program (TCRT-ESO-A2). GenScript ProBio extends congratulations on this.
GenScript ProBio and Eutilex Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for CAR-T Programs prnasia
April 07, 2020
GenScript Biotech Corporation's CDMO business GenScript ProBio (hereinafter referred to as GenScript ProBio) and Eutilex Co., Ltd. (hereinafter referred to as Eutilex) committed to developing anti-cancer immunotherapy technology jointly announced that the